Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Humana Healthy Horizons – Ohio partners with CPESN® USA to expand access to pharmacists
Humana Healthy Horizons – Ohio partners with CPESN® USA to expand access to pharmacists


Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana, announced it is partnering with CPESN® USA in Ohio to expand access to pharmacists for its members

Acadia Healthcare Accelerates Access to Care With Uber Health
Acadia Healthcare Accelerates Access to Care With Uber Health


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced a collaboration with Uber Health (NYSE:UBER). The two companies are coming together to improve access to life-saving behavioral health

Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence:
Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence


Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, and the University of California San Diego (UC San Diego), one of the top-ranked

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO  THE NUMBER OF SHARES AND VOTING RIGHTS  MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Abivax reports 2023 financial results and operational update
EQS-News: Abivax reports 2023 financial results and operational update
EQS-News: Abivax reports 2023 financial results and operational update
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological

Agilent Launches New Advanced Dilution System to Increase Lab Efficiency:
Agilent Launches New Advanced Dilution System to Increase Lab Efficiency


Agilent Technologies Inc. (NYSE: A) today announced the launch of the Advanced Dilution System, the ADS 2, a new automation workflow solution that will increase productivity, lower cost of

Novocure to Report First Quarter 2024 Financial Results
Novocure to Report First Quarter 2024 Financial Results


Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will

Poxel to Report Its 2023 Annual Results by the End of April 2024
Poxel to Report Its 2023 Annual Results by the End of April 2024


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs
Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs


Novocure (NASDAQ: NVCR) gab heute bekannt, dass die klinische Phase-3-Studie METIS ihren primären Endpunkt erreicht hat und eine statistisch signifikante Verbesserung der Zeit bis zur

Acadia Healthcare Acquires Three Comprehensive Treatment Centers in North Carolina
Acadia Healthcare Acquires Three Comprehensive Treatment Centers in North Carolina


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has recently completed the acquisitions of three comprehensive treatment centers (“CTC”) in North Carolina.



Two of the

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update


Regulatory News:



OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer


Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for

Resolutions of the Annual Shareholders’ Meeting  of Sartorius Stedim Biotech S.A.
Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
ICON plc Schedules First Quarter 2024 Earnings Conference Call
ICON plc Schedules First Quarter 2024 Earnings Conference Call


ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2024 after the

Inogen To Present at 23rd Annual Needham Virtual Healthcare Conference
Inogen To Present at 23rd Annual Needham Virtual Healthcare Conference


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 23rd Annual

Savara Announces New Employment Inducement Grant
Savara Announces New Employment Inducement Grant


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.



On March 21

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the

EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023